EUVIMEDEUVIMED entdecken
Crossref

Percutaneous ventricular assist device for higher‐risk percutaneous coronary intervention in surgically ineligible patients: Indications and outcomes from the OPTIMUM study

Taishi Hirai iD, J Aaron Grantham, David E Kandzari, William Ballard, W Morris Brown, Keith B Allen, Ajay J Kirtane iD, Michael Argenziano, Robert W Yeh, Kamal Khabbaz, William Lombardi, John Lasala und 5 weitere

Catheterization and Cardiovascular Interventions · 2023

DOI: 10.1002/ccd.30834 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Catheterization and Cardiovascular Interventions, 2023. Verfasst von Taishi Hirai und 16 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, University of Missouri, Columbia, Missouri, USA. Hauptthemen laut MEDLINE: Percutaneous Coronary Intervention, Heart-Assist Devices. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: Boston Scientific Corporation, Abiomed.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Indications and outcomes for percutaneous ventricular assist device (pVAD) use in surgically ineligible patients undergoing percutaneous coronary intervention (PCI) remain poorly characterized.

Aims

We sought to describe the use and timing of pVAD and outcome in surgically ineligible patients.

Methods

Among 726 patients enrolled in the prospective OPTIMUM study, clinical and health status outcomes were assessed in patients who underwent pVAD‐assisted PCI and those without pVAD.

Results

Compared with patients not receiving pVAD ( N = 579), those treated with pVAD ( N = 142) more likely had heart failure, lower left ventricular ejection fraction (30.7 ± 13.6 vs. 45.9 ± 15.5, p < 0.01), and higher STS 30‐day predicted mortality (4.2 [2.1−8.0] vs. 3.3 [1.7−6.6], p = 0.01) and SYNTAX scores (36.1 ± 12.2, vs. 31.5 ± 12.1, p < 0.01). While the pVAD group had higher in‐hospital (5.6% vs. 2.2%, p = 0.046), 30‐day (9.0% vs. 4.0%, p = 0.01) and 6‐month (20.4% vs. 11.7%, p < 0.01) mortality compared to patients without pVAD, this difference appeared to be largely driven by significantly higher mortality among the 20 (14%) patients with unplanned pVAD use (30% in‐hospital mortality with unplanned PVAD vs. 1.6% with planned, p < 0.01; 30‐day mortality, 38.1% vs. 4.5%, p < 0.01). The degree of 6‐month health status improvement among survivors was similar between groups.

Conclusion

Surgically ineligible patients with pVAD‐assisted PCI had more complex baseline characteristics compared with those without pVAD. Higher mortality in the pVAD group appeared to be driven by very poor outcomes by patients with unplanned, rescue pVAD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Percutaneous Coronary InterventionHeart-Assist DevicesHumansStroke VolumeProspective StudiesTreatment OutcomeRetrospective StudiesVentricular Function, LeftShock, Cardiogenic

Stichwörter der Autor:innen

high-risk percutaneous coronary interventionpercutaneous ventricular assist devicequality of lifesurgical ineligible

Autor:innen und Institutionen

  • Division of Cardiology, University of Missouri, Columbia, Missouri, USA.
  • Saint Luke's Mid America Heart Institute, Kansas City, Missouri, USA.
  • Divison of Cardiology, University of Missouri Kansas City, Kansas City, Missouri, USA.
  • Piedmont Heart Institute, Atlanta, Georgia, USA.
  • Columbia University Irving Medical Center/NewYork-Presbyterian Hospital and the Cardiovascular Research Foundation, New York, New York, USA.
  • Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.

ORCID-Profile: Taishi Hirai, Ajay J Kirtane, Adam C Salisbury

Förderung

  • Boston Scientific Corporation
  • Abiomed

Zitieren

APA

Hirai, T., Grantham, J. A., Kandzari, D. E., Ballard, W., Brown, W. M., Allen, K. B., Kirtane, A. J., Argenziano, M., Yeh, R. W., Khabbaz, K., Lombardi, W., Lasala, J., Kachroo, P., Karmpaliotis, D., Gosch, K. L., Salisbury, A. C., & OPTIMUM Study Group (2023). Percutaneous ventricular assist device for higher‐risk percutaneous coronary intervention in surgically ineligible patients: Indications and outcomes from the OPTIMUM study. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.30834

Vancouver

Hirai T, Grantham JA, Kandzari DE, Ballard W, Brown WM, Allen KB, et al. Percutaneous ventricular assist device for higher‐risk percutaneous coronary intervention in surgically ineligible patients: Indications and outcomes from the OPTIMUM study. Catheterization and Cardiovascular Interventions. 2023. doi:10.1002/ccd.30834

BibTeX
@article{Hirai2023,
  author = {Hirai, Taishi and Grantham, J Aaron and Kandzari, David E and Ballard, William and Brown, W Morris and Allen, Keith B and Kirtane, Ajay J and Argenziano, Michael and Yeh, Robert W and Khabbaz, Kamal and Lombardi, William and Lasala, John and Kachroo, Puja and Karmpaliotis, Dimitri and Gosch, Kensey L and Salisbury, Adam C and OPTIMUM Study Group, OPTIMUM Study Group},
  title = {Percutaneous ventricular assist device for higher‐risk percutaneous coronary intervention in surgically ineligible patients: Indications and outcomes from the OPTIMUM study},
  journal = {Catheterization and Cardiovascular Interventions},
  year = {2023},
  doi = {10.1002/ccd.30834}
}
Kostenlos starten →